Affiliation:
1. Department of Dermatology, Cangzhou Central Hospital, No. 16 Xinhua Western Road, Cangzhou, 061000 Hebei
Province, P.R. China
Abstract
Objective:
Malignant melanoma with gastric cancer is one of the most malignant
tumors. However, there have been no reports on the effects of KAI1 and miRNA-633 on the survival
and prognosis of patients with malignant melanoma with gastric cancer.
Methods:
Fifty patients with malignant melanoma and gastric cancer were collected from October
2017 to December 2019. The clinical parameters included clinical information, such as sex, age,
tumor size, and tumor staging. RT-qPCR was used to detect the expression of KAI1 and miRNA-
633. The role of KAI1 and miRNA-633 on the overall survival of melanoma was explored by the
Pearson chi-square test, Spearman-rho correlation test, Univariate and multivariate cox regression
analyses, and Kaplan–Meier method. Furthermore, the bioinformatic analysis was used to verify
the role of KAI1 and miRNA-633 on malignant melanoma with gastric cancer.
Results:
The expression of KAI1 and miRNA-633 was significantly related with the tumor size
and staging of tumor (p<0.05) based on the Pearson chi-square test. Spearman’s correlation coefficient
displayed that KAI1 was significantly correlated with the miRNA-633 (ρ=-0.439, p=0.001).
The result of multivariate cox proportional regression analysis showed that KAI1 (HR =0.109,
95% CI: 0.031-0.375, p< 0.001), and miRNA-633 (HR = 13.315, 95% CI: 3.844-46.119, p<0.001)
were significantly associated with overall survival.
Conclusion:
The low expression level of KAI1 and high expression of miRNA-633 are significantly
correlated with the poor overall survival prognosis of malignant melanoma with gastric cancer,
to provide a basis for KAI1 and miRNA-633 to become novel molecular targets for malignant melanoma
with gastric cancer.
Funder
Youth Science and Technology project of the health and Health Commission of Shanxi province
Publisher
Bentham Science Publishers Ltd.
Subject
Organic Chemistry,Computer Science Applications,Drug Discovery,General Medicine
Reference34 articles.
1. De Smedt J.; Van Kelst S.; Boecxstaens V.; Stas M.; Bogaerts K.; Vanderschueren D.; Aura C.; Vandenberghe K.; Lambrechts D.; Wolter P.; Bechter O.; Nikkels A.; Strobbe T.; Emri G.; Marasigan V.; Garmyn M.; Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): A randomized controlled trial. BMC Cancer 2017,17(1),562
2. Jerant A.F.; Johnson J.T.; Sheridan C.D.; Caffrey T.J.; Early detection and treatment of skin cancer. Am Fam Physician 2000,62(2),357-368, 375-376, 381-382
3. Balch C.M.; Gershenwald J.E.; Soong S.J.; Thompson J.F.; Atkins M.B.; Byrd D.R.; Buzaid A.C.; Cochran A.J.; Coit D.G.; Ding S.; Eggermont A.M.; Flaherty K.T.; Gimotty P.A.; Kirkwood J.M.; McMasters K.M.; Mihm M.C.; Morton D.L.; Ross M.I.; Sober A.J.; Sondak V.K.; Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009,27(36),6199-6206
4. Hernandez B.Y.; Green M.D.; Cassel K.D.; Pobutsky A.M.; Vu V.; Wilkens L.R.; Preview of Hawaii cancer facts and figures 2010. Hawaii Med J 2010,69(9),223-224
5. Houghton A.N.; Polsky D.; Focus on melanoma. Cancer Cell 2002,2(4),275-278
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献